Skip to main content

Advertisement

Table 3 Most frequent adverse events (≥2% in any treatment arm)

From: Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children aged less than five years: results of an open-label, randomized, single-centre study

Adverse events AL dispersible (n = 238) DP paediatric (n = 231)
Patients with at least one adverse event 156 (65.54) 156 (67.53)
Malaria 61 (25.63) 42 (18.18)
Cough 37 (15.55) 40 (17.32)
Anaemia 10 (4.20) 8 (3.46)
Fever 7 (2.94) 14 (6.06)
Tinea capitis 10 (4.20) 12 (5.19)
Rhinitis 4 (1.68) 13 (5.63)
Gastroenteritis 9 (3.78) 5 (2.16)
Loss of appetite 3 (1.26) 6 (2.59)
Otitis media 7 (2.94) 5 (2.16)
  1. AL: Artemether-lumefantrine; DP: dihydroartemisinin-piperaquine.